Formycon Plans Ranibizumab Filings With Ustekinumab And Aflibercept In The Wings

 
• By Aidan Fry

Formycon will follow a US filing for ranibizumab before the end of this year with a European submission early in 2020 as it continues work on biosimilar ustekinumab and aflibercept.

Submit
Formycon is gearing up to file its FYB201 ranibizumab biosimilar candidate for approval in the US and the EU • Source: Shutterstock

More from Biosimilars

More from Products